Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer

Z. Timsah, Z. Ahmed, C. Ivan, J. Berrout, M. Gagea, Y. Zhou, G. N.A. Pena, X. Hu, C. Vallien, C. V. Kingsley, Y. Lu, J. F. Hancock, J. Liu, A. B. Gladden, Gordon Mills, G. Lopez-Berestein, M. C. Hung, A. K. Sood, M. Bogdanov, J. E. Ladbury

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In the absence of extracellular stimulation the adaptor protein growth factor receptor-bound protein (Grb2) and the phospholipase Plcγ1 compete for the same binding site on fibroblast growth factor receptor 2 (FGFR2). Reducing cellular Grb2 results in upregulation of Plcγ1 and depletion of the phospholipid PI(4,5)P 2. The functional consequences of this event on signaling pathways are unknown. We show that the decrease in PI(4,5)P 2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. This results in excessive cell proliferation and tumor progression in a xenograft mouse model. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plcγ1 and Grb2 correlate with patient survival. Oncogenesis through fluctuation in the expression levels of these proteins negates extracellular stimulation or mutation and defines them as novel prognostic markers in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)2186-2196
Number of pages11
JournalOncogene
Volume35
Issue number17
DOIs
StatePublished - Apr 28 2016
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 2
Ovarian Neoplasms
Neoplasms
Proteins
Growth Factor Receptors
Phospholipases
Oncogene Proteins
Heterografts
Phospholipids
Carcinogenesis
Up-Regulation
Binding Sites
Phosphorylation
Cell Proliferation
Mutation
Survival
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. / Timsah, Z.; Ahmed, Z.; Ivan, C.; Berrout, J.; Gagea, M.; Zhou, Y.; Pena, G. N.A.; Hu, X.; Vallien, C.; Kingsley, C. V.; Lu, Y.; Hancock, J. F.; Liu, J.; Gladden, A. B.; Mills, Gordon; Lopez-Berestein, G.; Hung, M. C.; Sood, A. K.; Bogdanov, M.; Ladbury, J. E.

In: Oncogene, Vol. 35, No. 17, 28.04.2016, p. 2186-2196.

Research output: Contribution to journalArticle

Timsah, Z, Ahmed, Z, Ivan, C, Berrout, J, Gagea, M, Zhou, Y, Pena, GNA, Hu, X, Vallien, C, Kingsley, CV, Lu, Y, Hancock, JF, Liu, J, Gladden, AB, Mills, G, Lopez-Berestein, G, Hung, MC, Sood, AK, Bogdanov, M & Ladbury, JE 2016, 'Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer', Oncogene, vol. 35, no. 17, pp. 2186-2196. https://doi.org/10.1038/onc.2015.279
Timsah, Z. ; Ahmed, Z. ; Ivan, C. ; Berrout, J. ; Gagea, M. ; Zhou, Y. ; Pena, G. N.A. ; Hu, X. ; Vallien, C. ; Kingsley, C. V. ; Lu, Y. ; Hancock, J. F. ; Liu, J. ; Gladden, A. B. ; Mills, Gordon ; Lopez-Berestein, G. ; Hung, M. C. ; Sood, A. K. ; Bogdanov, M. ; Ladbury, J. E. / Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. In: Oncogene. 2016 ; Vol. 35, No. 17. pp. 2186-2196.
@article{cdbe56049c33454a9e8d50528d1217b4,
title = "Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer",
abstract = "In the absence of extracellular stimulation the adaptor protein growth factor receptor-bound protein (Grb2) and the phospholipase Plcγ1 compete for the same binding site on fibroblast growth factor receptor 2 (FGFR2). Reducing cellular Grb2 results in upregulation of Plcγ1 and depletion of the phospholipid PI(4,5)P 2. The functional consequences of this event on signaling pathways are unknown. We show that the decrease in PI(4,5)P 2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. This results in excessive cell proliferation and tumor progression in a xenograft mouse model. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plcγ1 and Grb2 correlate with patient survival. Oncogenesis through fluctuation in the expression levels of these proteins negates extracellular stimulation or mutation and defines them as novel prognostic markers in ovarian cancer.",
author = "Z. Timsah and Z. Ahmed and C. Ivan and J. Berrout and M. Gagea and Y. Zhou and Pena, {G. N.A.} and X. Hu and C. Vallien and Kingsley, {C. V.} and Y. Lu and Hancock, {J. F.} and J. Liu and Gladden, {A. B.} and Gordon Mills and G. Lopez-Berestein and Hung, {M. C.} and Sood, {A. K.} and M. Bogdanov and Ladbury, {J. E.}",
year = "2016",
month = "4",
day = "28",
doi = "10.1038/onc.2015.279",
language = "English (US)",
volume = "35",
pages = "2186--2196",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "17",

}

TY - JOUR

T1 - Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer

AU - Timsah, Z.

AU - Ahmed, Z.

AU - Ivan, C.

AU - Berrout, J.

AU - Gagea, M.

AU - Zhou, Y.

AU - Pena, G. N.A.

AU - Hu, X.

AU - Vallien, C.

AU - Kingsley, C. V.

AU - Lu, Y.

AU - Hancock, J. F.

AU - Liu, J.

AU - Gladden, A. B.

AU - Mills, Gordon

AU - Lopez-Berestein, G.

AU - Hung, M. C.

AU - Sood, A. K.

AU - Bogdanov, M.

AU - Ladbury, J. E.

PY - 2016/4/28

Y1 - 2016/4/28

N2 - In the absence of extracellular stimulation the adaptor protein growth factor receptor-bound protein (Grb2) and the phospholipase Plcγ1 compete for the same binding site on fibroblast growth factor receptor 2 (FGFR2). Reducing cellular Grb2 results in upregulation of Plcγ1 and depletion of the phospholipid PI(4,5)P 2. The functional consequences of this event on signaling pathways are unknown. We show that the decrease in PI(4,5)P 2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. This results in excessive cell proliferation and tumor progression in a xenograft mouse model. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plcγ1 and Grb2 correlate with patient survival. Oncogenesis through fluctuation in the expression levels of these proteins negates extracellular stimulation or mutation and defines them as novel prognostic markers in ovarian cancer.

AB - In the absence of extracellular stimulation the adaptor protein growth factor receptor-bound protein (Grb2) and the phospholipase Plcγ1 compete for the same binding site on fibroblast growth factor receptor 2 (FGFR2). Reducing cellular Grb2 results in upregulation of Plcγ1 and depletion of the phospholipid PI(4,5)P 2. The functional consequences of this event on signaling pathways are unknown. We show that the decrease in PI(4,5)P 2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. This results in excessive cell proliferation and tumor progression in a xenograft mouse model. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plcγ1 and Grb2 correlate with patient survival. Oncogenesis through fluctuation in the expression levels of these proteins negates extracellular stimulation or mutation and defines them as novel prognostic markers in ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84937822650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937822650&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.279

DO - 10.1038/onc.2015.279

M3 - Article

C2 - 26212011

AN - SCOPUS:84937822650

VL - 35

SP - 2186

EP - 2196

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 17

ER -